Abdominal wall blocks in robotic hysterectomy for endometrial cancer are associated with a modest reduction in the frequency of patients receiving post-operative intravenous opioids
Ioana Bondre , H. Meryem Soylu , Francesca Corbetta , Breana Hill , Elise Wilson , Rodney Gabriel , Ramez Eskander , Michael McHale , Cheryl Saenz , Pratibha Binder , Steven Plaxe
{"title":"Abdominal wall blocks in robotic hysterectomy for endometrial cancer are associated with a modest reduction in the frequency of patients receiving post-operative intravenous opioids","authors":"Ioana Bondre , H. Meryem Soylu , Francesca Corbetta , Breana Hill , Elise Wilson , Rodney Gabriel , Ramez Eskander , Michael McHale , Cheryl Saenz , Pratibha Binder , Steven Plaxe","doi":"10.1016/j.gore.2025.101995","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the association of abdominal wall blocks at the time of robotic hysterectomy performed for endometrial cancer (EC) with in-hospital post-operative opioids.</div></div><div><h3>Methods</h3><div>We performed a retrospective cohort study of patients in the Vizient database<!--> <!-->who had robotic hysterectomy for EC between January 2019 and December 2022. The exposure was any<!--> <!-->block coded separate from the surgery, and the primary outcomes were any IV/oral opioid. Fentanyl was excluded due to frequent intra-op<!--> <!-->use. Length of stay (LOS) and<!--> <!-->direct cost<!--> <!-->were compared. The association between block and opioid use<!--> <!-->was assessed via risk ratio. The quantity of each opioid was expressed in standard resource units (SRU) – a metric<!--> <!-->used to standardize the consumption of medications across facilities.</div></div><div><h3>Results</h3><div>Three hundred and twenty of the 9062 patients (3.5 %) had a block and 8,742 (96.5 %) did not. Blocks were performed at 66 (20.4 %) hospitals.<!--> <!-->184 patients (57.5 %) in the block group received an IV opioid vs 5,890 (67.4 %) of the<!--> <!-->patients without a block (RR 0.85, 95 % CI 0.77–0.94, p < 0.001). Patients who received blocks were less likely to receive IV (52.5 % vs 64.8 %, RR 0.81, 95 % CI 0.73–0.89, p < 0.001)<!--> <!-->and oral hydromorphone (6.9 % vs 3.9 %, RR 2.53, 95 % CI 1.68–3.81, p < 0.001)<!--> <!-->and more likely to receive oral hydrocodone/acetaminophen (11.3 % vs 0.88 %, RR 12.77, 95 % CI 8.73–18.67, p < 0.001).</div></div><div><h3>Conclusion</h3><div>Blocks are infrequently performed and<!--> <!-->are associated with a modest reduction in the number of patients receiving post-op IV opioids.<!--> <!-->We found no difference<!--> <!-->in<!--> <!-->LOS or cost. Limitations include lack of detail regarding type of block, anesthetic, and phase of care.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"63 ","pages":"Article 101995"},"PeriodicalIF":1.5000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352578925003200","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To evaluate the association of abdominal wall blocks at the time of robotic hysterectomy performed for endometrial cancer (EC) with in-hospital post-operative opioids.
Methods
We performed a retrospective cohort study of patients in the Vizient database who had robotic hysterectomy for EC between January 2019 and December 2022. The exposure was any block coded separate from the surgery, and the primary outcomes were any IV/oral opioid. Fentanyl was excluded due to frequent intra-op use. Length of stay (LOS) and direct cost were compared. The association between block and opioid use was assessed via risk ratio. The quantity of each opioid was expressed in standard resource units (SRU) – a metric used to standardize the consumption of medications across facilities.
Results
Three hundred and twenty of the 9062 patients (3.5 %) had a block and 8,742 (96.5 %) did not. Blocks were performed at 66 (20.4 %) hospitals. 184 patients (57.5 %) in the block group received an IV opioid vs 5,890 (67.4 %) of the patients without a block (RR 0.85, 95 % CI 0.77–0.94, p < 0.001). Patients who received blocks were less likely to receive IV (52.5 % vs 64.8 %, RR 0.81, 95 % CI 0.73–0.89, p < 0.001) and oral hydromorphone (6.9 % vs 3.9 %, RR 2.53, 95 % CI 1.68–3.81, p < 0.001) and more likely to receive oral hydrocodone/acetaminophen (11.3 % vs 0.88 %, RR 12.77, 95 % CI 8.73–18.67, p < 0.001).
Conclusion
Blocks are infrequently performed and are associated with a modest reduction in the number of patients receiving post-op IV opioids. We found no difference in LOS or cost. Limitations include lack of detail regarding type of block, anesthetic, and phase of care.
目的探讨子宫内膜癌(EC)机器人子宫切除术时腹壁阻滞与院内阿片类药物的关系。方法:我们对Vizient数据库中2019年1月至2022年12月期间因EC接受机器人子宫切除术的患者进行了回顾性队列研究。暴露是与手术分开的,主要结果是静脉/口服阿片类药物。芬太尼因术中频繁使用被排除在外。比较住院时间(LOS)和直接费用。通过风险比评估阻滞和阿片类药物使用之间的关系。每种阿片类药物的数量以标准资源单位(SRU)表示,这是一种用于标准化各设施药物消耗的度量。结果9062例患者中有320例(3.5%)发生阻滞,8742例(96.5%)未发生阻滞。66家(20.4%)医院实施阻滞。阻断组184例患者(57.5%)接受静脉注射阿片类药物,未阻断组5890例患者(67.4%)(RR 0.85, 95% CI 0.77-0.94, p < 0.001)。接受阻断治疗的患者较少接受静脉注射(52.5% vs 64.8%, RR 0.81, 95% CI 0.73-0.89, p < 0.001)和口服氢吗啡酮(6.9% vs 3.9%, RR 2.53, 95% CI 1.68-3.81, p < 0.001),更可能接受口服氢可酮/对乙酰氨基酚(11.3% vs 0.88%, RR 12.77, 95% CI 8.73-18.67, p < 0.001)。结论阻滞很少发生,并且与术后接受静脉注射阿片类药物的患者数量适度减少有关。我们发现LOS和成本没有差异。局限性包括缺乏关于阻滞类型、麻醉和护理阶段的细节。
期刊介绍:
Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.